Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Saturday, May 31, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward hematologists/oncologists, medical oncologists, nurses, nurse practitioners, physician assistants, and other health care providers involved in the treatment and management of acute myeloid leukemia (AML).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate individualized treatment plans for patients with AML based on guideline-directed molecular testing and risk stratification
- Assess emerging treatment strategies for AML across frontline and relapsed/refractory settings
- Apply findings from recent clinical trials to optimize AML treatment approaches
- Implement proactive strategies to monitor and manage treatment-related adverse events in patients with AML
Gail J. Roboz, MD
Professor of Medicine
Director, Leukemia Program
Weill Cornell Medicine
New York-Presbyterian Hospital
New York, NY
Disclosures: Consultant: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, Celgene, Daiichi Sankyo, Ellipses Pharma, Genoptix GlaxoSmithKline, Geron, Glycomimetics, Janssen, Jasper Pharmaceuticals, Jazz Pharmaceuticals, Molecular Partners, Morphosys, Neogenomics, Novartis, Oncoprecision, Oncoverity, Pfizer, Rigel, Roche, Syndax; Grant/Research Support: Janssen
Hagop Kantarjian, MD
Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Consultant: AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Pfizer, Takeda; Grant/Research Support: AbbVie, Amgen, Ascentage, Pfizer, Takeda
Catherine Lai, MD, MPH
Associate Professor
Physician Leader, Leukemia Clinical Research Unit
Perelman Center for Advanced Medicine
University of Pennsylvania
Philadelphia, PA
Disclosures: Advisor: Arcellx, BioAscent, Daiichi Sankyo, Rigel, Servier, Syndax, Taiho Oncology; Consultant: AbbVie, Genentech, Rigel
Amer Zeidan, MBBS, MHS
Professor of Medicine
Director of Hematologic Malignancies
Yale University School of Medicine
Yale Cancer Center
New Haven, CT
Disclosures: Consultant: AbbVie, Agios, Akeso Pharma, ALX Oncology, Amgen, Astellas, BeiGene, BioCryst, Boehringer-Ingelheim, Bristol-Meyers Squibb, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Faron, Genentech, Geron, Gilead, Glycomimetics, Hikma, Janssen, Karyopharm, Keros, Kura, Kyowa Kirin, Lava Therapeutics, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Servier, Sumitomo, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, Zentalis; Grant/Research Support: AbbVie, Amgen, Astex, Bristol-Meyers Squibb, Celgene, Geron, Kura, Novartis, Otsuka, Shattuck Labs, Syros.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.